Phaseline

Targets › CDK4

CDK4 (Cyclin-dependent kinase 4): drug programs, companies and trials

46 programs from 37 companies in 264 trials: 138 Phase 2, 71 Phase 1, 49 Phase 3, 6 Phase 4; Oncology, Other, Gastroenterology; next expected readout Nov 2026.

Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1)…. (UniProt, P11802)

Open in Phaseline: the race on CDK4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisRibociclib (LEE011)
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 4Metastatic Breast Cancer; Early Breast Cancer; Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies; Breast Cancer …Dec 2026
Ottawa Hospital Research InstituteCDK4/6 inhibitor
Cyclin-dependent kinase 4/6 inhibitor
CDK4, CDK6Phase 4Metastatic Breast CancerMar 2027
PharmacosmosTrilaciclib
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 4Extensive-stage Small-cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Osteosarcoma; Head and Neck Cancer Squamous Cell Carcinoma …Oct 2027
Eli LillyAbemaciclib (LY2835219)
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 3Non Small Cell Lung Cancer; Breast Cancer; Breast Neoplasms; Prostatic Neoplasms …Nov 2026
BeOne MedicinesBGB-43395
Cyclin-dependent kinase 4 inhibitor
CDK4Phase 3HR+/HER2- Breast Cancer; Healthy Adult Participants; Hormone-receptor-positive Breast Cancer; Advanced Solid TumorNov 2026
Chia Tai Tianqing Pharmaceutical GroupTQB3616 capsule
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 3HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast CancerDec 2026
PfizerPalbociclib
CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor
CCND1, CDK6, CDK4Phase 3Breast Cancer; Ewing Sarcoma; Breast Cancer Recurrent; Metastatic Breast Cancer …Dec 2026
Shandong Suncadia MedicineHRS-8080
CDK4/6 inhibitor
CDK4, CDK6Phase 3Locally Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Unresectable or Metastatic Breast Cancer …Dec 2026
Fudan UniversityDalpiciclib (SHR6390)
CDK4/6 inhibitor
CDK4, CDK6Phase 3Advanced Breast Cancer; Breast CancerFeb 2027
PfizerPF-07220060
CDK4 inhibitor
CDK4Phase 3Breast Cancer; Advanced or Metastatic Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer; LiposarcomaFeb 2027
Fudan UniversityDalpiciclib (SHR-6390)
Cyclin-dependent kinase 4/6 inhibitor
CDK4, CDK6Phase 3Breast Cancer; Breast Cancer Metastatic; Breast NeoplasmJun 2027
Jiangsu Simcere PharmaceuticalTrilaciclib
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 3MyelosuppressionJul 2027
Tokyo Medical and Dental UniversityCDK4/6 inhibitor
CDK4/6 inhibitor combined with hormonal therapy (aromatase inhibitor or fulvestrant) with
CDK4, CDK6Phase 3Breast CancerNov 2029
Fudan UniversityDalpicilib
CDK4/6 inhibitor
CDK4, CDK6Phase 3Breast CancerSep 2030
Jiangsu HengRui MedicineSHR6390
CDK4/6 inhibitor
CDK4, CDK6Phase 3Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast CancerOct 2031
Fujian Cancer Hospitaldalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 3Breast Cancer; Breast DiseasesDec 2031
SWOG Cancer Research NetworkCyclin-Dependent Kinase 4/6 Inhibitor
CDK4/6 inhibitor
CDK4, CDK6Phase 3Anatomic Stage IV Breast Cancer AJCC v8May 2032
Hebei Medical University Fourth HospitalDalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerDec 2026
Shengjing HospitalSHR6390
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerDec 2026
Tianjin Medical University Cancer Institute and HospitalDalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2CANCER; Non-small Cell Lung CancerDec 2026
Sun Yat-sen UniversityDalpiciclib Isetionate Tablets
CDK4/6 inhibitor
CDK4, CDK6Phase 2Hepatocellulcar Carcinoma; Advanced/Metastatic Breast CancerDec 2026
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCDK4/6 inhibitor
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerAug 2027
Peking UniversityDalpiciclib Isethionate
CDK4/6 inhibitor
CDK4, CDK6Phase 2Esophageal Squamous Cell CarcinomaOct 2027
Washington University School of MedicinePD0332991
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast NeoplasmsNov 2027
Shengjing HospitalDalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerDec 2027
University of California, San DiegoA CDK4/6 inhibitor different from the first that the participant had received, p
CDK4/6 inhibitor plus fulvestrant (selective estrogen receptor degrader)
CDK4, CDK6Phase 2Breast CancerDec 2027
AstraZenecaAtirmociclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Advanced Breast CancerDec 2027
Canadian Cancer Trials GroupRP-6306 (Lunresertib)
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerDec 2027
Zhejiang Cancer Hospitaldalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerDec 2027
Henan Cancer HospitalDalpiciclib Isethionate Tablets
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast NeoplasmsJan 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2HR+/HER2- Early Breast CancerMay 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineFovinaciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2HR+/HER2+ Early Breast CancerMay 2028
Fudan UniversityCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2Breast CancerJun 2028
The First Affiliated Hospital with Nanjing Medical UniversityCulmerciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerAug 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCulmerciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Hormone Receptor-Positive Breast CancerSep 2028
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universitydalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Salivary Gland CarcinomaOct 2028
Sun Yat-sen UniversityCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2Breast CancerDec 2028
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityDalpicilib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaDec 2028
Peking University People's HospitalDalpiciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Hormone Receptor-Positive Breast CancerDec 2029
UNC Lineberger Comprehensive Cancer CenterSelective Estrogen Receptor Degrader (SERD)
CDK4/6 inhibitor
CDK4, CDK6Phase 2Breast CancerJun 2031
Shanghai Hengrui PharmaceuticalSHR6390
CDK4/6 inhibitor
CDK4, CDK6Phase 1ER-Positive, HER2-Negative Breast CancerDec 2026
Tasly PharmaceuticalsTSL2109
CDK4/6-DYRK2 dual-target inhibitor
CDK4, CDK6, DYRK2Phase 1Metastatic Castration-Resistant Prostate Cancer PatientsDec 2026
University of WashingtonSamuraciclib
CDK4/6 inhibitor
CDK4, CDK6Phase 1Resectable Pancreatic Ductal AdenocarcinomaJul 2027
NiKang TherapeuticsNKT5097
CDK2/CDK4 dual degrader
CDK2, CDK4Phase 1HR+ Breast CancerJul 2027
PfizerAtirmociclib
CDK4/6 inhibitor
CDK4, CDK6Phase 1Hepatic ImpairmentAug 2027
Avenzo TherapeuticsAVZO-023
CDK4 inhibitor
CDK4Phase 1HR+/HER2- Breast CancerAug 2028

Conditions

Breast Cancer (62) Metastatic Breast Cancer (13) Breast Neoplasms (8) HR+/HER2- Breast Cancer (5) Advanced Breast Cancer (5) Endometrial Cancer (4) Early Breast Cancer (3) Breast Cancer Female (3) Estrogen-receptor-positive Breast Cancer (3) Anatomic Stage IV Breast Cancer AJCC v8 (3) Advanced Dedifferentiated Liposarcoma (3) Anatomic Stage II Breast Cancer AJCC v8 (2)

Modalities

small molecule (30), mixed (12), antibody (1), other (1), protein or peptide (1)

Companies

Fudan University (4) Pfizer (3) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) Shengjing Hospital (2) Sun Yat-sen University (2) Novartis (1) Pharmacosmos (1) Fujian Cancer Hospital (1) Peking University (1) BeOne Medicines (1) SWOG Cancer Research Network (1) Eli Lilly (1) Jiangsu HengRui Medicine (1) Avenzo Therapeutics (1) Shandong Suncadia Medicine (1) Chia Tai Tianqing Pharmaceutical Group (1) Tasly Pharmaceuticals (1) Hebei Medical University Fourth Hospital (1) Jiangsu Simcere Pharmaceutical (1)

Related targets

CDK6 (42) CDK2 (5) DYRK2 (1) CCND1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.